Wednesday, September 13, 2017 4:19:10 PM
Wait to buy again after the pricing....
Press Release: Array BioPharma Announces Proposed Public Offering of Common Stock
4:02 pm ET September 13, 2017 (Dow Jones) Print
Array BioPharma Announces Proposed Public Offering of Common Stock
PR Newswire
BOULDER, Colo., Sept. 13, 2017
BOULDER, Colo., Sept. 13, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common stock. Array BioPharma also intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Array BioPharma.
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the proposed offering. Piper Jaffray & Co. is also acting as a bookrunner for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The shares are being offered by Array BioPharma pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (SEC) and became effective. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC, and will be available on the SEC's website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, telephone: 866-803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York, 11717, Attn: Prospectus Department, telephone: 631-274-2806; or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department, telephone: 800-747-3924.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the proposed public offering. These statements involve significant risks and uncertainties, including those discussed in the preliminary prospectus supplement related to the offering and in our most recent annual report filed on Form 10-K. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. There can be no assurance that Array BioPharma will be able to complete the offering. We are providing this information as of September 13, 2017. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
CONTACT: Tricia Haugeto, Array BioPharma
(303) 386-1193
thaugeto@arraybiopharma.com
Recent ARRY News
- Array Technologies, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call • GlobeNewswire Inc. • 04/18/2024 08:05:10 PM
- Array Technologies Launches Hail Alert Response • GlobeNewswire Inc. • 03/26/2024 01:00:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:49:59 AM
- Array Technologies, Inc. Reports Financial Results for the Fourth Quarter and Full Year 2023; Full year 2023 net income of $86 million; Record full year Adjusted EBITDA of $288 million • GlobeNewswire Inc. • 02/27/2024 09:05:20 PM
- US Index Futures Slightly Rise; Bitcoin Reaches 2021 High • IH Market News • 02/27/2024 11:16:30 AM
- Array Technologies and Alupco® Announce Strategic Partnership to Fuel Growing Renewable Energy Market in the Middle East • GlobeNewswire Inc. • 02/22/2024 11:18:07 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:40:56 PM
- Array Technologies, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call • GlobeNewswire Inc. • 02/06/2024 09:05:45 PM
- GM Layoffs, Costco Announces $15 Dividend, Intel’s AI Chip Line, and More • IH Market News • 12/15/2023 02:04:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/15/2023 02:55:35 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/15/2023 02:54:01 AM
- Array Technologies Appoints Solar Industry Veteran Jessica Lawrence-Vaca as Senior Vice President, Policy and External Affairs • GlobeNewswire Inc. • 12/06/2023 09:10:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 10:59:29 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/17/2023 02:26:56 PM
- Wednesday’s Wall Street Highlights: Spirit AeroSystems, Upstart, Toast, Upwork, Take-Two, Sleep Number, and more • IH Market News • 11/08/2023 11:59:53 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 10:25:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:24:03 PM
- Array Technologies, Inc. Reports Financial Results for the Third Quarter 2023 – Continues strong operational execution; announced Chief Financial Officer transition • GlobeNewswire Inc. • 11/07/2023 09:10:02 PM
- Array Technologies Introduces Integrated Field Services and Customer Training Offerings to US Customers • GlobeNewswire Inc. • 11/03/2023 12:45:00 PM
- Gov. Lujan Grisham and Array Technologies Announce N.M. Expansion • GlobeNewswire Inc. • 11/02/2023 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 11:04:37 PM
- Array Technologies, Inc. Announces Third Quarter 2023 Earnings Release Date and Conference Call • GlobeNewswire Inc. • 10/17/2023 08:05:18 PM
- Array Technologies Strengthens Domestic Supply Chain Through Base Load Agreement with Steel Dynamics • GlobeNewswire Inc. • 09/12/2023 12:45:00 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM